THE EFFECT OF L-DOPA INFUSIONS WITH AND WITHOUT PHENYLALANINE CHALLENGES IN PARKINSONIAN-PATIENTS - PLASMA AND VENTRICULAR CSF L-DOPA LEVELS AND CLINICAL-RESPONSES

被引:21
|
作者
WOODWARD, WR
OLANOW, CW
BECKNER, RM
HAUSER, RA
GAUGER, LL
CEDARBAUM, JM
NUTT, JG
机构
[1] UNIV S FLORIDA,DEPT NEUROL,TAMPA,FL 33620
[2] UNIV S FLORIDA,DEPT PHARMACOL & EXPTL THERAPEUT,TAMPA,FL 33620
[3] CORNELL UNIV,MED CTR,DEPT NEUROL,NEW YORK,NY 10021
[4] OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201
[5] OREGON HLTH SCI UNIV,DEPT PHARMACOL,PORTLAND,OR 97201
关键词
D O I
10.1212/WNL.43.9.1704
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We monitored the motor response and plasma and ventricular CSF (CSF(v)) concentrations of L-dopa during IV infusions of L-dopa in two patients with advanced Parkinson's disease. Concentrations Of L-dopa in CSF(v) mirrored, but lagged behind, those in plasma. In the fasting state, the duration, but not the magnitude, of the motor response was greater with increasing plasma and CSF(v) levels Of L-dopa. During IV infusions of L-dopa following oral administration of phenylalanine, a large neutral amino acid that shares a transport system into the brain with L-dopa, the duration of the motor response was markedly attenuated despite undiminished CSF(v) levels of L-dopa. These observations suggest that either L-dopa entry into CSF(v) and the brain are differentially affected by phenylalanine or that phenylalanine affects other steps in the motor response. These observations demonstrate that, except in the fasting state, L-dopa in CSF(v) is not a reliable predictor of motor response.
引用
收藏
页码:1704 / 1708
页数:5
相关论文
共 50 条
  • [21] REVIEW OF PARKINSONIAN PATIENTS TREATED SURGICALLY AND BY L-DOPA
    NITTNER, K
    [J]. CONFINIA NEUROLOGICA, 1974, 36 (4-6): : 360 - 361
  • [22] SULFATE CONJUGATION AND L-DOPA TREATMENT OF PARKINSONIAN PATIENTS
    RUTLEDGE, CO
    HOEHN, MM
    [J]. NATURE, 1973, 244 (5416) : 447 - 450
  • [23] MENTAL SYMPTOMS IN PARKINSONIAN PATIENTS TREATED WITH L-DOPA
    HERSON, RN
    [J]. LANCET, 1970, 2 (7675): : 721 - &
  • [24] INFLUENCE OF L-DOPA ON NIGHT SLEEP IN PARKINSONIAN PATIENTS
    KENDEL, K
    WITA, C
    ZIMMERMANN, H
    BECK, U
    HOHNECK, E
    [J]. ARCHIV FUR PSYCHIATRIE UND NERVENKRANKHEITEN, 1972, 216 (01): : 82 - +
  • [25] DOES L-DOPA IMPROVE THE ABILITY OF PARKINSONIAN-PATIENTS TO PERFORM TIMED REPETITIVE MOVEMENTS
    FREEMAN, JS
    OBOYLE, DJ
    CODY, FWJ
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 1994, 475P : P22 - P23
  • [26] EFFECT OF SMALL DOSES OF L-DOPA ON EXCRETION WITH URINE OF CATECHOLAMINES AND L-DOPA IN PATIENTS WITH SCHIZOPHRENIA
    VASILEV, VN
    [J]. VOPROSY MEDITSINSKOI KHIMII, 1980, 26 (06): : 782 - 786
  • [27] Apomorphine SC treatment in parkinsonian patients with long term L-DOPA syndrome during L-DOPA drug holiday
    Scarzella, L
    Delsedime, M
    Ferrero, B
    Giangrandi, C
    Priano, L
    Rizzone, M
    Bergamasco, B
    [J]. JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1995, (45): : 163 - 170
  • [28] ABSENCE OF RELATIONSHIPS BETWEEN L-DOPA PLASMA-LEVELS AND THERAPEUTIC EFFECT IN PARKINSONS-DISEASE TREATED WITH L-DOPA
    ALGERI, S
    RUGGIERI, S
    MIRANDA, F
    CASACCHIA, M
    MORSELLI, PL
    AGNOLI, A
    [J]. EUROPEAN NEUROLOGY, 1976, 14 (03) : 219 - 228
  • [29] PLASMA LEVELS OF DOPA AND CATECHOLAMINES AFTER ORAL ADMINISTRATION OF L-DOPA
    IMAI, K
    SUGIURA, M
    TAMURA, Z
    HIRAYAMA, K
    NARABAYASHI, H
    [J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 1971, 19 (02) : 439 - +
  • [30] EFFECT OF L-DOPA ON PLASMA TSH LEVELS IN PRIMARY HYPOTHYROIDISM
    MINOZZI, M
    FAGGIANO, M
    LOMBARDI, G
    CARELLA, C
    CRISCUOLO, T
    SCAPAGNINI, U
    [J]. NEUROENDOCRINOLOGY, 1975, 17 (02) : 147 - 153